A Phase I Study of Venetoclax + Lenalidomide + Rituximab Hyaluronidase in Relapsed or Refractory (R/R) Indolent Non-Hodgkin's Lymphoma (iNHL).
Latest Information Update: 28 May 2025
At a glance
- Drugs Hyaluronidase/rituximab (Primary) ; Lenalidomide (Primary) ; Rituximab (Primary) ; Venetoclax (Primary)
- Indications Follicular lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions
Most Recent Events
- 22 May 2025 Planned End Date changed from 31 Mar 2025 to 30 Jun 2025.
- 22 May 2025 Status changed from recruiting to active, no longer recruiting.
- 06 Jun 2024 Planned End Date changed from 31 Mar 2024 to 31 Mar 2025.